This 2017 year-in-review highlights the expanding role of TAVR in intermediate-risk patients and summarizes key trials on procedural adjuncts and newer valve technologies.
TAVR foothold in intermediate-risk patients extends prior data; leaves optimal cerebral protection and antiplatelet regimens open for further trials.
This article is a continuation of our previously published annual reviews of transcatheter aortic valve replacement (TAVR). In 2017, TAVR further established a foothold in the management of intermediate risk patients with the publication of SURTAVI trial. Randomized trials also addressed the use of cerebral protection during TAVR and single versus dual antiplatelet therapy after TAVR. Newer generation valve systems continued to be studied for their efficacy and safety. This paper summarizes the major studies published in 2017.
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: